Cryoballoon Ablation for Patients With Paroxysmal Atrial Fibrillation

Kazuyoshi Suenari, MD; Takayuki Nakano, MD; Shunsuke Tomomori, MD; Nobuo Shiode, MD; Satoshi Higa, MD; Shih-Ann Chen, MD

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, inducing cardiac dysfunction and stroke. The development of AF requires a trigger and also an electroanatomic substrate capable of both initiating and perpetuating AF. In the past decade, ectopic beats originating from the pulmonary veins (PV) have been identified as a source of paroxysmal AF. Thus, strategies that target the PV, including the PV antrum, are the cornerstone of most AF ablation procedures. Recently, alternative technologies to radiofrequency catheter ablation for paroxysmal AF such as balloon ablation modalities have been developed. The purpose of this review is to discuss cryoballoon ablation for paroxysmal AF.

Key Words: Atrial fibrillation; Catheter ablation; Cryoballoon

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice, inducing cardiac dysfunction and stroke. AF depends on the interaction between triggers and anatomical substrates, and the isolation of the pulmonary veins (PV) and elimination of non-PV triggers form the basis of an AF ablation strategy that is highly effective in most patients with paroxysmal AF. Therefore, point-by-point ablation of the circumference of the PV using an irrigated-tip radiofrequency (RF) catheter is the cornerstone of therapy for symptomatic paroxysmal AF refractory to anti-arrhythmic drugs. Recently, advanced balloon ablation technology using a variety of energy modalities, such as cryoballoon (CB; Arctic-Front Advance; Medtronic, Minneapolis, MN, USA), hot balloon (Toray Industries, Tokyo, Japan), and laser balloon (HeartLight; CardioFocus, Marlborough, MA, USA), which are placed in the PV ostia to isolate the PV circumferentially, has become available for the treatment of paroxysmal AF. Multiple studies for each balloon ablation technology have proven that each technology is as effective as RF catheter ablation (RFCA) in treating paroxysmal AF. The balloon ablation modalities, however, have various challenges that need to be overcome, such as the need for additional touch-up ablation; the durability of balloon-based PV isolation; anatomical difficulties; and complications including PV stenosis, thromboembolic complications, cardiac perforation with pericardial tamponade, esophageal fistula, and phrenic nerve palsy (PNP). Further development of the technology and methodology of balloon-based ablation is therefore needed, in order to reduce these problems.

In this article, we review the current clinical experience of CB ablation in the treatment of paroxysmal AF.

Catheter Ablation of Paroxysmal AF

According to the expert consensus statement, catheter ablation is recommended for symptomatic paroxysmal AF refractory to anti-arrhythmic drugs (class I/level of evidence A), or it may even be considered as first-line therapy, after weighing the risks of the ablation procedure (class IIa/B). PV isolation is the cornerstone of catheter ablation strategies for AF, especially the paroxysmal condition. Numerous studies have shown that the elimination of PV triggers could lead to better long-term clinical outcomes for paroxysmal AF patients. Human and animal studies and computer simulation models have also indicated that the wave front arising from the rotor area with high dominant frequency (DF) accompanying peripheral heterogeneous activation through an inhomogeneous atrial substrate gives rise to fibrillatory conduction. The highest incidence of wavebreaks and the beat-to-beat variability in the direction and velocity of wave front propagation have also been shown to be associated with highly fractionated atrial signals located at the boundaries of the high DF regions. Several clinical studies reported that complex fractionated atrial electrograms were observed at adjacent areas with high DF in patients with paroxysmal and non-paroxysmal AF. Lin et al reported that the highest DF was located in the arrhythmogenic PV or its ostium in the PV-AF patients, and that those patients also had a significant frequency gradient from the PV ostium to the left atrium (LA). Similarly, a recent study demonstrated a close relationship between the arrhythmogenic PV and the critical...
has emerged as an effective therapy to treat paroxysmal AF and has become a substitute for RFCA due to the advantage of easier catheter manipulation and shorter procedure time compared with RFCA. The efficacy and safety of CB ablation therapy have also been shown to be similar to those of RFCA in patients with paroxysmal AF.

For paroxysmal AF patients without advanced structural remodeling of the PV and LA, the 28-mm CB could be sufficient to ablate a large area including the PV antrum, similar to the area obtained in wider circumferential ipsilateral PV isolation using RFCA.

Evolution of CB Technology

Cryotherapy has a long history of use as a treatment for frostbite and tumor destruction. The ridged, hand-held cryothermal ablation probes have been used for surgical arrhythmia treatment since the 1970s. As described previously, the mechanism of cryoablation is based on the Joule-Thomson effect (the change in temperature of an expanding gas) to achieve tissue temperatures between −30°C and −90°C. Cryoablation is realized through the delivery of pressurized cryorefrigerant (currently liquefied nitrous oxide) to the distal aspect of the inner balloon via an ultrafine injection tube. Nitrous oxide has a boiling temperature of −88.47°C, providing adequate cooling power and safety margins for use in cardiac tissue ablation. As the refrigerant cools, ice forms at the tissue contact site, causing the balloon to adhere to the tissue, stabilizing it in place for the duration of freezing. Progressive cooling to below −40°C results in the formation of intracellular ice crystals. Cell and tissue damage, however, occur both during the freezing process and afterward, in sequential stages (freeze, thaw, hemorrhage and reactive inflammation, and replacement fibrosis). The extent of scarring yielding electrically silent tissues depends on the acute damage phase (the freeze/thaw cycle), and involves several variables. As compared with RFCA lesions, cryoablation lesions result in preservation of tissue architecture with less damage to large vascular structures or to the endocardium. Histologically, cryothermy results in the creation of well-demarcated homogeneous lesions that are

Table. Clinical Trials of CB Ablation in Patients With Paroxysmal AF

| Trial          | Publication year (ref. no.) | n (CB/RF) | AF type | Generation of CB | CB procedure | Average CB application time (s) | Procedure time (min) | Mean follow-up (months) | Primary endpoints/outcome |
|----------------|-----------------------------|-----------|---------|------------------|--------------|-------------------------------|----------------------|--------------------------|--------------------------|
| FIRE and ICE   | 2016 (8)                    | 374/376   | PAF     | 1st and 2nd     | 300 s (CB1), 240 s (CB2) | 124.4 ± 140.9       | 124.4 ± 39.8, 92.3 ± 31.4 | 18                       | 65.4% (CB) vs. 64.1% (RF) |
| CRYO-Japan     | 2016 (47)                   | 616 (CB)  | PAF     | 2nd              | 180–240 s LS,†, 115.4 ± 33.2, RI,†, 150.4 ± 33.5 | 150.2 ± 48.9, 95.9 ± 35.4 | 6                       | 88.4%                    |
| STOP AF PAS    | 2019 (50)                   | 344 (CB)  | PAF     | 2nd              | 240 s         | 214.4 ± 1.5                   | 80.4 ± 31.4           | 36                       | 64%                      |
| RADICOOL       | 2018 (48)                   | 452 (CB)  | PAF     | 2nd              | 180 or 240 s  | N/A                           | N/A                  | 12                       | 87%                      |
| FREEZE AF      | 2019 (49)                   | 2,329/1,860 | PAF (70.4%) | 1st, 2nd, 3rd    | N/A          | N/A                           | N/A                  | 63                       | 69.3% (CB) vs. 60.8% (RF) |
| ESC-EHRA registry | 2019 (51)              | 982/3,675 | PAF (75.4%) | 2nd              | N/A          | 133.6 ± 174.6                 | N/A                  | 36                       | 70.2% (CB) vs. 68.2% (RF) |

†Using 28-mm CB. AF, atrial fibrillation; CB, cryoballoon; CB1/2, first-/second-generation CB; LA, left atrium; LI, left inferior; LS, left superior; PAF, paroxysmal atrial fibrillation; RF, radiofrequency; RI, right inferior; RS, right superior.

Evolution of CB Technology

Cryotherapy has a long history of use as a treatment for frostbite and tumor destruction. The ridged, hand-held cryothermal ablation probes have been used for surgical arrhythmia treatment since the 1970s. As described previously, the mechanism of cryoablation is based on the Joule-Thomson effect (the change in temperature of an expanding gas) to achieve tissue temperatures between −30°C and −90°C. Cryoablation is realized through the delivery of pressurized cryorefrigerant (currently liquefied nitrous oxide) to the distal aspect of the inner balloon via an ultrathin injection tube. Nitrous oxide has a boiling temperature of −88.47°C, providing adequate cooling power and safety margins for use in cardiac tissue ablation. As the refrigerant cools, ice forms at the tissue contact site, causing the balloon to adhere to the tissue, stabilizing it in place for the duration of freezing. Progressive cooling to below −40°C results in the formation of intracellular ice crystals. Cell and tissue damage, however, occur both during the freezing process and afterward, in sequential stages (freeze, thaw, hemorrhage and reactive inflammation, and replacement fibrosis). The extent of scarring yielding electrically silent tissues depends on the acute damage phase (the freeze/thaw cycle), and involves several variables. As compared with RFCA lesions, cryoablation lesions result in preservation of tissue architecture with less damage to large vascular structures or to the endocardium. Histologically, cryothermy results in the creation of well-demarcated homogeneous lesions that are

Figure 1. Comparison of the second-generation and fourth-generation cryoballoons (CB2 and CB4, respectively). The CB4 has a shorter tip to enhance visualization of pulmonary vein (PV) potential by enabling more proximal placement of the Achieve mapping catheter in the PV.
Cryoballoon Ablation for PAF

First-generation equipment, the CB2 ablation devices have a better cooling capacity and seem to reduce the procedure duration. Real-time PV potential monitoring during CB application is feasible with an over-the-wire mapping catheter (Achieve), and monitoring of the time from the beginning of cryofreezing until PV isolation is now possible. CB2 has a high procedural success rate and convincing clinical outcome data for paroxysmal AF. The FIRE AND ICE trial proved the non-inferiority of CB2- to RF-based PV isolation with regard to efficacy and safety for treatment of PAF. In consequence, the latest AF ablation guidelines state that PV isolation should be performed using either RF or CB catheters. In general, CB ablation protocols predominantly use a fixed freeze cycle duration of 180–240 s (Table), often followed by a bonus freeze cycle. Recently, modified freezing protocols aimed at shorter and fewer CB applications have demonstrated similar clinical outcomes.

After identifying the time to PV isolation (TTI) as an essential indicator of durable PV isolation, the latest ablation strategies have been implemented the individual TTI. The weakness of CB2, however, is that TTI could be less arrhythmogenic and thrombogenic than the ragged, indistinct lesions associated with RFCA.

The use of cryoablation for PV isolation may offer certain advantages. The tissue-catheter adhesion during cryoablation can result in improved catheter stability for creating lesions. The cryoablation is associated with reduced pain and discomfort given that the afferent pain fibers are frozen as opposed to stimulated thermally. Cryoablation also has a lower risk of thrombus formation and, consequently, of systemic thromboembolic stroke, because it is associated with decreased activation of platelets and of the coagulation cascade as compared with RFCA lesions. Cryoablation leaves the connective tissue matrix intact and decreases the risk of steam pops. Furthermore, the lack of circulation, around the center of the cryoablation lesion results in uniform tissue necrosis. Thus, the cryoablation lesions result in preservation of tissue architecture with less damage to large vascular structures or to the endocardium as compared with RFCA lesions.

The introduction of second-generation CB (CB2) has improved balloon based-PV isolation. Compared with first-generation equipment, the CB2 ablation devices have a better cooling capacity and seem to reduce the procedure duration. Real-time PV potential monitoring during CB application is feasible with an over-the-wire mapping catheter (Achieve), and monitoring of the time from the beginning of cryofreezing until PV isolation is now possible. CB2 has a high procedural success rate and convincing clinical outcome data for paroxysmal AF. The FIRE AND ICE trial proved the non-inferiority of CB2- to RF-based PV isolation with regard to efficacy and safety for treatment of PAF. In consequence, the latest AF ablation guidelines state that PV isolation should be performed using either RF or CB catheters. In general, CB ablation protocols predominantly use a fixed freeze cycle duration of 180–240 s (Table), often followed by a bonus freeze cycle. Recently, modified freezing protocols aimed at shorter and fewer CB applications have demonstrated similar clinical outcomes.

After identifying the time to PV isolation (TTI) as an essential indicator of durable PV isolation, the latest ablation strategies have been implemented the individual TTI. The weakness of CB2, however, is that TTI could be

Figure 2. Representative cryoballoon (CB) procedure in a patient with paroxysmal atrial fibrillation (AF). (A) A single transseptal puncture was performed using a radiofrequency (RF) needle (Baylis Medical, Montreal, QC, Canada) through an 8-Fr sheath (SL1, AF Division, Abbott/St. Jude Medical, Minneapolis, MN, USA) under intracardiac echocardiography (ICE) guidance (ViewFlex™ Xtra ICE catheter, Abbott/St. Jude Medical). (B) After transseptal puncture under ICE guidance, the SL1 sheath is advanced into the left atrium (LA) through the inner wire and pulled back into the right atrium (RA). (C) The FlexCath sheath is advanced into the LA via the transseptal puncture as a guide for the SL1 inner wire. (D) After the Optima mapping catheter is placed at the superior vena cava (SVC) through the SL1 sheath to observe the compound motor action potentials on the right side, the CB ablation procedure is started from the left superior pulmonary vein (PV), followed by the left inferior PV, the right inferior PV, and the right superior PV.
Abbott/St. Jude Medical) is placed at the SVC through the SL1 sheath to monitor the diaphragmatic compound motor action potentials (CMAP) during phrenic nerve pacing for each CB application at right PV (Figure 2D). The 4-Fr deflectable 4-pole electrode catheter is placed into the apex of the right ventricle for sudden AV block during the CB procedure. PV isolation was performed with a single balloon technique using a CB2 (the CB4 has been available since April 2019). A 28-mm CB catheter was used in all of the patients. A spiral mapping catheter (Achieve, Medtronic) was used to advance the CB and map the PV potentials. Complete sealing at the antral aspect of the PV was confirmed on injection of contrast medium. The freezing protocol has been applied based on the CRYO-Japan PMS study.

An 11–20-mm or 15–25-mm circular mapping catheter (Inquiry TM Optima TM , Abbott/St. Jude Medical, St. Paul, MN, USA), according to PV diameter, was used to map all of the PV after CB applications to confirm electrical isolation. If electrical isolation was not achieved, additional touch-up ablation was performed with a conventional RF catheter.

CB Ablation: Precautions

Although CB ablation has emerged as an effective, alternative treatment option to traditional point-by-point RFCA for paroxysmal AF, there are several issues with CB ablation. Knowledge of the close anatomical relationships between the PV, the right phrenic nerve, esophagus and the bronchial tree is critical to understanding why these structures are prone to collateral injury during CB ablation. This collateral injury is usually associated with a low nadir balloon temperature. In several multi-center clinical trials, the common major complication was PNP, including transient injury, which has been seen in 3.2–13.5%. In contrast, almost zero patients in the RFCA group had PNP. We also encountered 2 cases of transient PNP. Figure 3 shows the recovery process in one of them with PNP after CB ablation. Recently, the continuous monitoring recorded only in 55–85% of cases, even at experienced centers. The longer distal tip of the CB2 limits proper visualization of PV potentials because it prevents proximal positioning of the Achieve catheter close to the CB’s surface (Figure 1). The third-generation CB (CB3) incorporates a 40% shorter tip, facilitating a more proximal Achieve catheter position. As a consequence, a higher rate of real-time PV recordings was noted for the CB3 compared with CB2.42,43 In October 2018, a fourth-generation CB (CB4) was released (Figure 1), and it has been available for use in Japan since April 2019. The CB4 with a shorter distal tip is safe and effective, and allows determination of TTI in 78–85% of PV.44–46 Several randomized clinical trials have been carried out to investigate the efficacy and long-term outcomes of CB ablation (Table), which were almost identical to those of RFCA.47–51 Furthermore, CB-based PV isolation seems to be less operator dependent and more reproducible than RF-based PV isolation in the setting of paroxysmal AF ablation, although various parts of the procedure, such as the freezing protocol, were not standardized.

CB Ablation Technique

Many researchers worldwide have reported on the CB ablation technique.47–51 CB ablation is simple and fast, even in the hands of beginners, as compared with RFCA, despite the learning curve needed to master the skills of CB ablation.53–55 In brief, a single transseptal puncture is made using an RF needle (Baylis Medical, Montreal, QC, Canada) through an 8-Fr sheath (SL1, AF Division, Abbott/St. Jude Medical, Minneapolis, MN, USA) under intracardiac echocardiography guidance (ViewFlex™ Xtra ICE catheter, Abbott/St. Jude Medical, Figure 2A, B). Then, a 15-Fr steerable sheath (FlexCath Advance, Medtronic) is inserted into the LA as a guide for the wire of the SL1 sheath (Figure 2C). After the Flexcath sheath is inserted into the LA, the SL1 sheath is placed at the superior vena cava (SVC). A spiral circular mapping catheter (Optima; Abbreviation: CB, cryoballoon; RFCA, radiofrequency catheter ablation; PNP, phrenic nerve palsy; TTI, total time index; PV, pulmonary vein; LA, left atrium; ICE, intracardiac echocardiography; AF, atrial fibrillation.)
Cryoballoon Ablation for PAF

Cryoballoon Ablation for PAF

noted on emergency coronary angiography (Figure 4B).

Regarding unusual complications, late onset coronary spasm after CB ablation has been reported.58 We also encountered a similar case of late-onset coronary spasm after CB procedure. Although no remarkable change was noted on 12-lead electrocardiogram (ECG) during CB ablation (Figure 4A), the ST segment in the inferior leads gradually rose approximately 30 min after the CB procedure, and a severe spasm of the right coronary artery was noted on emergency coronary angiography (Figure 4B). The CB procedure induces acute and late-onset coronary artery spasm in susceptible patients,58 which is suggested to be modulated by CB by imbalance in the autonomic nerve system via affected ganglionated plexi close to the PV ostium. The 12-lead ECG should be continuously monitored throughout the procedure with special attention to ischemic changes.

Furthermore, attention is needed to confirm the isolation of CMAP has become standard in clinical practice, and this involves immediate termination with a single or double stop technique when the CMAP significantly decreases.

Figure 4. Representative case of severe spasm in the right coronary artery after cryoballoon ablation (CBA). (A) On surface electrocardiogram (ECG) the inferior leads showed ST-segment elevation, and emergency coronary angiography of the right coronary artery showed severe spasm. (B) After intracoronary injection of nitroglycerine, the right coronary artery spasm and surface ECG resolved. ISP, isoproterenol; LIPV, left inferior pulmonary vein; LSPV, left superior pulmonary vein; RIPV, right inferior pulmonary vein; RSPV, right superior pulmonary vein;
of carina regions after CB ablation (Figure 5). Takigawa et al reported that a double-Lasso guided ipsilateral PV isolation may miss a non-isolation of the PV carina. In that study, the PV carina in 21% of patients remained non-isolated after the procedure.59 Furthermore, the existence of non-isolated PV carina even after double-Lasso guided successful PV isolation was an independent predictor of AF recurrence during a mean follow-up of 19±13 months.59 In our patient, residual PV potential was detected at the right PV carina region even after successful Achieve catheter-guided CB ablation (Figure 5C). Additional RF applications in the PV antral area using a 4-mm open-irrigated tip catheter (FlexAbility™, Abbott/St. Jude Medical) completely eliminated the residual conduction between the LA and right PV (Figure 5D). Even though isolation of all PV is confirmed by Achieve catheter after CB ablation, a myocardial connection between the right PV carina and LA may persist after CB ablation, which may require additional RF applications. Therefore, careful mapping around each PV including the carina region is necessary to ensure complete electrical PV antral isolation after CB ablation.

Minimally Invasive and Tailored CB Ablation

There are differences in CB protocol between institutions (Table). Acute PV isolation is a well-known physiological predictor of durable isolation if real-time acute PV isolation can be monitored using the Achieve mapping catheter.44 Time to PV isolation, however, has been documented in all targeted PV in only 37% patients.60 Thus, it could be difficult to determine the end-point of cryotherapy using monitoring of time to PV isolation. The optimal dosage of cryotherapy to achieve durable PV isolation is still unclear. Creatine kinase (CK) has been reported to be significantly increased after CB ablation as compared with RF ablation.61,62 Moreover, Casella et al reported that troponin I and CK-MB were significantly increased after CB ablation as compared with after ablation with other energy sources.63 This strongly indicates that CB ablation could induce great myocardial injury. Thus, unnecessary CB applications could lead to severe collateral complications, even though the locations of residual PV-LA conduction breakthrough were usually only limited points.64 Furthermore, lower nadir balloon temperature and longer application could lead to collateral injuries.65 Recently, several studies have investigated ways to reduce cryotherapy time.65,66 Pot et al reported that CB ablation with TTI-guided cryoenergy titration could be non-inferior to the fixed CB ablation strategy.66 Their TTI-guided CB ablation protocol was modified such that freeze duration was 120s for TTI <30s, and 180s for TTI 30–60s, and the fixed CB ablation protocol included
Circulation Reports Vol.2, February 2020

a 240-s bonus freeze following freeze cycles of 240 s.** TTIs guided cryoenergy titration leads to reduced procedure duration and fluoroscopy time and appears to be as effective as a fixed ablation strategy. In the Pott et al study, real-time PV isolation was observed in 81.5% of PV.** CB4 could record real-time online PV potential with a low incidence of CB dislodgment.** Further research into tailored CB ablation protocols using CB4 to reduce unnecessary cryoenergy applications is required.

**Conclusions**

The evolution of CB ablation as a single-shot effective and safe ablation approach targeted at the PV triggers in paroxysmal AF has generated a huge surge of interest in this technique. CB ablation may be able to control this most common cardiac arrhythmia by producing a lasting sinus rhythm. Further, these technological advances could result in better procedure guidance and more durable lesions. The new CB4, with a 40% shortened tip compared with the previous version, was recently introduced in an attempt to improve the visualization of real-time recording of PV potentials during the CB procedure, and thus, can more clearly visualize TTI, which is an important predictor of successful and durable PV isolation.** The technological progress that has led to this tailored minimally invasive approach for avoiding excessive cryotherapy to the atrium and collateral damage, as described in this review, will need further study to explore and elucidate the pathophysiological mechanisms of this most common arrhythmia.

**Disclosures**

S.H. is a consultant to Japan Life Line and Johnson & Johnson, and has received Speaker's Honoraria from Abbott, Bayer, Biotronik, Boehringer-Ingelheim, Bristol-Myers, Daiichi-Sankyo Pharmaceutical Company, and Pfizer. The other authors declare no conflicts of interest.

**References**

1. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. *Am J Med* 1995; 98: 476–484.

2. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation* 1997; 96: 2455–2461.

3. Nattel S. New ideas about atrial fibrillation 50 years on. *Nature 2002; 415: 219–226.

4. Wyse DG, Gersh BJ. Atrial fibrillation: A perspective: Thinking inside and outside the box. *Circulation* 2004; 109: 3089–3095.

5. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quinio G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998; 339: 659–666.

6. Chen SA, Hsieh MH, Tai CT, Tsai CF, Prakash VS, Yu WC, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: Electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. *Circulation* 1999; 100: 1879–1886.

7. Lin WS, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. *Circulation* 2003; 107: 3176–3183.

8. Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *N Engl J Med* 2016; 374: 2235–2245.

9. Sohara H, Ohe T, Okumura K, Naito S, Hirao K, Shoda M, et al. HotBalloon ablation of the pulmonary veins for paroxysmal AF: A multicenter randomized trial in Japan. *J Am Coll Cardiol* 2016; 68: 2747–2757.

10. Schmidt B, Neuzil P, Luik A, Osca Asensi J, Schrickel JW, Deneket T, et al. Laser balloon or wide-area circumferential irrigated radiofrequency ablation for persistent atrial fibrillation: A multicenter prospective randomized study. *Circ Arrhythm Electrophysiol* 2017; 10: e005767.

11. Miyazaki S, Tada H. Complications of cryoballoon pulmonary vein isolation. *Arrhythm Electrophysiol Rev* 2019; 8: 60–64.

12. Falkins H, Hindricks G, Canuto R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Heart Rhythm* 2017; 14: e275–e444.

13. Skanes AC, Mandapati R, Berenfeld O, Davidenko JM, Jalife J. Spatiotemporal periodicity during atrial fibrillation in the isolated sheep heart. *Circulation* 1998; 98: 1236–1248.

14. Berenfeld O, Mandapati R, Dixit S, Skanes AC, Chen J, Mansour M, et al. Spatially distributed dominant excitation frequencies reveal hidden organization in atrial fibrillation in the Langendorff-perfused sheep heart. *J Cardiovasc Electrophysiol* 2000; 11: 869–879.

15. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. *Circulation* 2000; 101: 194–199.

16. Relatiis S, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. Spatially distributed dominant excitation frequencies reveal hidden organization in atrial fibrillation in the isolated sheep heart. *Circulation* 2000; 101: 194–199.

17. Lin YJ, Tai CT, Kao T, Chang SL, Lo LW, Tuan TC, et al. Spatiotemporal organization of the left atrial substrate after circumferential pulmonary vein isolation of atrial fibrillation. *Circ Arrhythm Electrophysiol* 2009; 2: 233–241.

18. Stiles MK, Brooks AG, Kulkik P, John B, Dimitri H, Lau DH, et al. High-density mapping of atrial fibrillation in humans: Relationship between high-frequency activation and electrogram fractionation. *J Cardiovasc Electrophysiol* 2008; 19: 1245–1253.

19. Lin YJ, Tai CT, Kao T, Tsao HW, Higa S, Tsao HM, et al. Frequency analysis in different types of paroxysmal atrial fibrillation. *J Am Coll Cardiol* 2006; 47: 1401–1407.

20. Suemori K, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, et al. Relationships between arrhythmogenic pulmonary veins and the surrounding atrial substrate in patients with paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol* 2011; 22: 405–410.

21. Vogt J, Heintze J, Gutleben KJ, Muntean B, Horstkotte D, Nolker G. Long-term outcomes after cryoballoon pulmonary vein isolation: Results from a prospective study in 605 patients. *J Am Coll Cardiol* 2013; 61: 1707–1712.

22. Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: The prospective, randomized, controlled, controlled, noninferiority FreezeAF Study. *Circulation* 2015; 132: 1311–1319.

23. Holda MK, Klimiek-Piotrowska W, Holda J. Cryoballoon or radiofrequency ablation for atrial fibrillation. *N Engl J Med* 2016; 375: 1100.

24. Lin YJ, Tsai CF, Prakash VS, Yu WC, et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. *Circulation* 2003; 107: 3176–3183.

25. Kuck KH, Brugada J, Furnkranz A, Chun KR, Metzner A, Ouyang F, Schluter M, et al. Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: Reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial. *Europ Heart J* 2016; 37: 2858–2865.

26. Cronin EM, Wisnouwsky BJ, Rizzo RA, Niehauer MJ, Dressing TJ, Cantillon DJ. Real-time guidewire localization using impedance-based electroanatomic mapping: Experimental results and clinical validation during cryoballoon ablation of atrial fibrillation. *Europace* 2013; 15: 1669–1676.

27. Miyazaki S, Taniguchi H, Hachiya H, Nakamura H, Takagi T, Iwasawa J, et al. Quantitative analysis of the isolation area during the chronic phase after a 28-mm second-generation cryoballoon ablation demarcated by high-resolution electroanatomic mapping. *Circ Arrhythm Electrophysiol* 2016; 9: e003879.

28. Gallagher JJ, Sealy WC, Anderson RW, Kasell J, Millar R, Campbell RW, et al. Cryosurgical ablation of accessory atrioventricular connections: A method for correction of the pre-excitation syndrome. *Circulation* 1977; 55: 471–479.

29. Harrison L, Gallagher JJ, Kasell J, Anderson RH, Mikat E, Hackel DB, et al. Cryoablation of the A-V node-His bundle: A new method for producing A-V block. *Circulation* 1977; 55: 463–470.

30. Gallagher JJ, Anderson RW, Kasell J, Rice JR, Pritchett EL, Gault HJ, et al. Cryoablation of drug-resistant ventricular tachycardia in a patient with a variant of scleroderma. *Circulation* 1978; 57: 191–197.

31. Piccini JP, Daubert JP. Cryoablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2002; 13: 1154–1160.
